HY-P990289 Search Results


nude mice cd24 antibody treatment  (MedChemExpress)
92
MedChemExpress nude mice cd24 antibody treatment
A, IC 50 values for AMG 510 in two mice KRAS G12C cell lines was determined by MTT assay. B , CyTOF immune profiling by viSNE of KRAS G12C mouse pancreatic tumors with vehicle or AMG 510 treatment. C , Representative viSNE plots of macrophage populations in KRAS G12C mouse pancreatic tumor with vehicle or AMG 510 treatment. D, IHC of xenograft tumors showing phosphor-ERK was reduced whereas CD8 + T cells and F4/80 + macrophages were increased in AMG 510-treated tumors compared to vehicle-treated group. E, CyTOF analysis demonstrates that <t>CD24</t> intensity was upregulated in cancer cells after AMG 510 treatment. Left , quantification of CD24 intensity. Right , representative viSNE plots of CD24 staining in tumors with vehicle or AMG 510 treatment. Data, mean ± SEM; n = 3. F, Median of membrane CD24+ in 49725 K C PC cancer cells treated with vehicle or AMG 510 was measured by flow cytometry. Data, mean ± SEM. G, Median of membrane CD24+ (top) or CD47+ (bottom) in 50760 K C PC cancer cells treated with vehicle or AMG 510 was measured by flow cytometry. Data, mean ± SEM. H, Kinase array analysis indicated that AMG 510 treatment in 50760 K C PC cancer cells results in decrease of p-ERK and p-c-Jun and increase of p-STAT3 (Y705). I, Western blots of whole-cell lysates from vehicle, AMG 510 or AMG 510 plus C188-9 treated 50760 K C PC cancer cell lines.
Nude Mice Cd24 Antibody Treatment, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 92/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/nude mice cd24 antibody treatment/product/MedChemExpress
Average 92 stars, based on 1 article reviews
nude mice cd24 antibody treatment - by Bioz Stars, 2026-02
92/100 stars
  Buy from Supplier
anti-mouse cd172a antibody  (MedChemExpress)
N/A
Anti-Mouse CD172a Antibody (P84) is a rat-derived anti-mouse CD172a IgG1 κ type antibody inhibitor. Anti-Mouse CD172a Antibody (P84) blocks CD47-SIRPα interaction and thereby augments cell phagocytosis. Anti-Mouse CD172a Antibody (P84) can be used for the
   Buy from Supplier

Image Search Results


A, IC 50 values for AMG 510 in two mice KRAS G12C cell lines was determined by MTT assay. B , CyTOF immune profiling by viSNE of KRAS G12C mouse pancreatic tumors with vehicle or AMG 510 treatment. C , Representative viSNE plots of macrophage populations in KRAS G12C mouse pancreatic tumor with vehicle or AMG 510 treatment. D, IHC of xenograft tumors showing phosphor-ERK was reduced whereas CD8 + T cells and F4/80 + macrophages were increased in AMG 510-treated tumors compared to vehicle-treated group. E, CyTOF analysis demonstrates that CD24 intensity was upregulated in cancer cells after AMG 510 treatment. Left , quantification of CD24 intensity. Right , representative viSNE plots of CD24 staining in tumors with vehicle or AMG 510 treatment. Data, mean ± SEM; n = 3. F, Median of membrane CD24+ in 49725 K C PC cancer cells treated with vehicle or AMG 510 was measured by flow cytometry. Data, mean ± SEM. G, Median of membrane CD24+ (top) or CD47+ (bottom) in 50760 K C PC cancer cells treated with vehicle or AMG 510 was measured by flow cytometry. Data, mean ± SEM. H, Kinase array analysis indicated that AMG 510 treatment in 50760 K C PC cancer cells results in decrease of p-ERK and p-c-Jun and increase of p-STAT3 (Y705). I, Western blots of whole-cell lysates from vehicle, AMG 510 or AMG 510 plus C188-9 treated 50760 K C PC cancer cell lines.

Journal: bioRxiv

Article Title: KRAS inhibition activates an actionable CD24 ‘don’t eat me’ signal in pancreas cancer

doi: 10.1101/2023.09.21.558891

Figure Lengend Snippet: A, IC 50 values for AMG 510 in two mice KRAS G12C cell lines was determined by MTT assay. B , CyTOF immune profiling by viSNE of KRAS G12C mouse pancreatic tumors with vehicle or AMG 510 treatment. C , Representative viSNE plots of macrophage populations in KRAS G12C mouse pancreatic tumor with vehicle or AMG 510 treatment. D, IHC of xenograft tumors showing phosphor-ERK was reduced whereas CD8 + T cells and F4/80 + macrophages were increased in AMG 510-treated tumors compared to vehicle-treated group. E, CyTOF analysis demonstrates that CD24 intensity was upregulated in cancer cells after AMG 510 treatment. Left , quantification of CD24 intensity. Right , representative viSNE plots of CD24 staining in tumors with vehicle or AMG 510 treatment. Data, mean ± SEM; n = 3. F, Median of membrane CD24+ in 49725 K C PC cancer cells treated with vehicle or AMG 510 was measured by flow cytometry. Data, mean ± SEM. G, Median of membrane CD24+ (top) or CD47+ (bottom) in 50760 K C PC cancer cells treated with vehicle or AMG 510 was measured by flow cytometry. Data, mean ± SEM. H, Kinase array analysis indicated that AMG 510 treatment in 50760 K C PC cancer cells results in decrease of p-ERK and p-c-Jun and increase of p-STAT3 (Y705). I, Western blots of whole-cell lysates from vehicle, AMG 510 or AMG 510 plus C188-9 treated 50760 K C PC cancer cell lines.

Article Snippet: For nude mice CD24 antibody treatment, mice were injected intraperitoneally 100 μg of CD24 antibody (ATG-031; cat#HY-P99176; MCE) twice a week.

Techniques: MTT Assay, Staining, Membrane, Flow Cytometry, Western Blot

A, B, Left , Growth curves of xenograft tumors ( A ,49725; B , 50760) show change in tumor volume over vehicle or AMG 510 treatment. Data, mean ± SEM. Right , Waterfall plot of vehicle- and AMG 510-treated tumors showing a change in tumor volume after treatment compared with baseline at day 0. Each bar represents a single tumor. C, Quantification of the immune cell populations by CyTOF immune profiling. Data, mean ± SEM; n = 3. The statistical difference between vehicle and AMG 510 treated groups was determined by two-tailed t tests. D, Quantification of macrophage populations by CyTOF analysis. Data, mean ± SEM; n = 3. E , Representative viSNE plots of p-SHP2+ macrophage populations in KRAS G12C mouse pancreatic tumor with vehicle or AMG 510 treatment. F , Quantification of p-SHP2+ macrophage populations in E . Data, mean ± SEM; n = 3. G , Median of membrane CD24+ in 50760 K C PC cancer cells treated with vehicle or AMG 510 was measured by flow cytometry. Data, mean ± SEM; the statistical difference between experimental groups was determined by two-tailed t tests. H , qRT-PCR for CD24 expression in 50760 K C PC cancer cells treated with vehicle or AMG 510. Data, mean ± SEM; n = 3. The statistical difference was determined by two-tailed t tests. I , Western blots of whole-cell lysates from vehicle or AMG 510 treated 50760 K C PC cancer cell lines. J , Median of membrane CD24+ in 50760 K C PC cancer cells treated with vehicle, AMG 510 or AMG plus C188-9 was measured by flow cytometry. Data, mean ± SEM; the statistical difference between experimental groups was determined by two-tailed t tests. K , qRT-PCR for CD24 expression in 50760 K C PC cancer cells treated with vehicle, AMG 510 or AMG plus C188-9. Data, mean ± SEM; n = 3. The statistical difference was determined by two-tailed t tests. L , In vitro phagocytosis of mouse 50760-GFP PDAC cells cocultured with macrophage cell line RAW264.7 in the presence of AMG 510, anti-CD24 mAb, or dual treatment vs. IgG control. Phagocytosis was measured as the number of F4/80+, GFP+ macrophages, quantified as a percentage of the total F4/80+ macrophages. Data, mean ± SEM; n = 3. Statistics with significance were indicated n.s. not significant; * P <0.05; ** P <0.01; ***, P < 0.001, **** P <0.0001.

Journal: bioRxiv

Article Title: KRAS inhibition activates an actionable CD24 ‘don’t eat me’ signal in pancreas cancer

doi: 10.1101/2023.09.21.558891

Figure Lengend Snippet: A, B, Left , Growth curves of xenograft tumors ( A ,49725; B , 50760) show change in tumor volume over vehicle or AMG 510 treatment. Data, mean ± SEM. Right , Waterfall plot of vehicle- and AMG 510-treated tumors showing a change in tumor volume after treatment compared with baseline at day 0. Each bar represents a single tumor. C, Quantification of the immune cell populations by CyTOF immune profiling. Data, mean ± SEM; n = 3. The statistical difference between vehicle and AMG 510 treated groups was determined by two-tailed t tests. D, Quantification of macrophage populations by CyTOF analysis. Data, mean ± SEM; n = 3. E , Representative viSNE plots of p-SHP2+ macrophage populations in KRAS G12C mouse pancreatic tumor with vehicle or AMG 510 treatment. F , Quantification of p-SHP2+ macrophage populations in E . Data, mean ± SEM; n = 3. G , Median of membrane CD24+ in 50760 K C PC cancer cells treated with vehicle or AMG 510 was measured by flow cytometry. Data, mean ± SEM; the statistical difference between experimental groups was determined by two-tailed t tests. H , qRT-PCR for CD24 expression in 50760 K C PC cancer cells treated with vehicle or AMG 510. Data, mean ± SEM; n = 3. The statistical difference was determined by two-tailed t tests. I , Western blots of whole-cell lysates from vehicle or AMG 510 treated 50760 K C PC cancer cell lines. J , Median of membrane CD24+ in 50760 K C PC cancer cells treated with vehicle, AMG 510 or AMG plus C188-9 was measured by flow cytometry. Data, mean ± SEM; the statistical difference between experimental groups was determined by two-tailed t tests. K , qRT-PCR for CD24 expression in 50760 K C PC cancer cells treated with vehicle, AMG 510 or AMG plus C188-9. Data, mean ± SEM; n = 3. The statistical difference was determined by two-tailed t tests. L , In vitro phagocytosis of mouse 50760-GFP PDAC cells cocultured with macrophage cell line RAW264.7 in the presence of AMG 510, anti-CD24 mAb, or dual treatment vs. IgG control. Phagocytosis was measured as the number of F4/80+, GFP+ macrophages, quantified as a percentage of the total F4/80+ macrophages. Data, mean ± SEM; n = 3. Statistics with significance were indicated n.s. not significant; * P <0.05; ** P <0.01; ***, P < 0.001, **** P <0.0001.

Article Snippet: For nude mice CD24 antibody treatment, mice were injected intraperitoneally 100 μg of CD24 antibody (ATG-031; cat#HY-P99176; MCE) twice a week.

Techniques: Two Tailed Test, Membrane, Flow Cytometry, Quantitative RT-PCR, Expressing, Western Blot, In Vitro, Control

A, B, Top, Growth curves of xenograft K C PC tumors ( A ,49725; B , 50760) show change in tumor volume over vehicle, anti-CD24, AMG 510 or anti-CD24 + AMG 510 treatment. Data, mean ± SEM. Bottom , Waterfall plot of vehicle-, anti-CD24-, AMG 510- or anti-CD24 + AMG 510-treated tumors showing a change in tumor volume after treatment compared with baseline at day 0. Each bar represents a single tumor. C , In vivo phagocytosis. Mouse 50760-GFP PDAC cells were injected into the right flank of C57BL/6 mice and treated with IgG control or AMG 510+ anti-CD24 mAb for 14 days. Mice tumor tissues were collected for flow cytometry. Phagocytosis was measured as the number of F4/80+, GFP+ macrophages, quantified as a percentage of the total F4/80+ macrophages. Data, mean ± SEM; n = 4. D , Mice tumor tissues collected in C were measured by flow cytometry for F4/80 and p-SHP2. Percentage of p-SHP2+ macrophages were compared in IgG control or AMG 510+ anti-CD24 mAb groups. Data, mean ± SEM; n = 4. E , Growth curves of xenograft K C PC tumor (49725) show changes in tumor volume over vehicle, vehicle + anti-CSF1R, anti-CD24 + AMG 510 (combination), or anti-CSF1R + combination treatment. Data, mean ± SEM. F , Median of membrane CD24+ in K D PC cancer cells (55582) treated with vehicle or MRTX1133 was measured by flow cytometry. Data, mean ± SEM; the statistical difference between experimental groups was determined by two-tailed t tests. G , qRT-PCR for CD24 expression in K D PC cancer cells (55582) treated with vehicle or MRTX1133. Data, mean ± SEM; n = 3. The statistical difference was determined by two-tailed t tests. H , Left , Growth curves of xenograft K D PC tumor (55582) show change in tumor volume over vehicle, anti-CD24, MRTX1133 or anti-CD24 + MRTX1133 treatment. Data, mean ± SEM. Right , Waterfall plot of vehicle, anti-CD24, MRTX1133 or anti-CD24 + MRTX1133-treated tumors showing a change in tumor volume after treatment compared with baseline at day 0. Each bar represents a single tumor. I , Top , Growth curves of human KRAS G12D tumors (AsPC1) show change in tumor volume over vehicle, anti-CD24, MRTX1133 or anti-CD24 + MRTX1133 treatment. Data, mean ± SEM. Bottom, Waterfall plot of vehicle, anti-CD24, MRTX1133 or anti-CD24 + MRTX1133-treated tumors showing a change in tumor volume after treatment compared with baseline at day 0. Each bar represents a single tumor. Statistics with significance were indicated n.s. not significant; * P <0.05; ** P <0.01; ***, P < 0.001, **** P <0.0001.

Journal: bioRxiv

Article Title: KRAS inhibition activates an actionable CD24 ‘don’t eat me’ signal in pancreas cancer

doi: 10.1101/2023.09.21.558891

Figure Lengend Snippet: A, B, Top, Growth curves of xenograft K C PC tumors ( A ,49725; B , 50760) show change in tumor volume over vehicle, anti-CD24, AMG 510 or anti-CD24 + AMG 510 treatment. Data, mean ± SEM. Bottom , Waterfall plot of vehicle-, anti-CD24-, AMG 510- or anti-CD24 + AMG 510-treated tumors showing a change in tumor volume after treatment compared with baseline at day 0. Each bar represents a single tumor. C , In vivo phagocytosis. Mouse 50760-GFP PDAC cells were injected into the right flank of C57BL/6 mice and treated with IgG control or AMG 510+ anti-CD24 mAb for 14 days. Mice tumor tissues were collected for flow cytometry. Phagocytosis was measured as the number of F4/80+, GFP+ macrophages, quantified as a percentage of the total F4/80+ macrophages. Data, mean ± SEM; n = 4. D , Mice tumor tissues collected in C were measured by flow cytometry for F4/80 and p-SHP2. Percentage of p-SHP2+ macrophages were compared in IgG control or AMG 510+ anti-CD24 mAb groups. Data, mean ± SEM; n = 4. E , Growth curves of xenograft K C PC tumor (49725) show changes in tumor volume over vehicle, vehicle + anti-CSF1R, anti-CD24 + AMG 510 (combination), or anti-CSF1R + combination treatment. Data, mean ± SEM. F , Median of membrane CD24+ in K D PC cancer cells (55582) treated with vehicle or MRTX1133 was measured by flow cytometry. Data, mean ± SEM; the statistical difference between experimental groups was determined by two-tailed t tests. G , qRT-PCR for CD24 expression in K D PC cancer cells (55582) treated with vehicle or MRTX1133. Data, mean ± SEM; n = 3. The statistical difference was determined by two-tailed t tests. H , Left , Growth curves of xenograft K D PC tumor (55582) show change in tumor volume over vehicle, anti-CD24, MRTX1133 or anti-CD24 + MRTX1133 treatment. Data, mean ± SEM. Right , Waterfall plot of vehicle, anti-CD24, MRTX1133 or anti-CD24 + MRTX1133-treated tumors showing a change in tumor volume after treatment compared with baseline at day 0. Each bar represents a single tumor. I , Top , Growth curves of human KRAS G12D tumors (AsPC1) show change in tumor volume over vehicle, anti-CD24, MRTX1133 or anti-CD24 + MRTX1133 treatment. Data, mean ± SEM. Bottom, Waterfall plot of vehicle, anti-CD24, MRTX1133 or anti-CD24 + MRTX1133-treated tumors showing a change in tumor volume after treatment compared with baseline at day 0. Each bar represents a single tumor. Statistics with significance were indicated n.s. not significant; * P <0.05; ** P <0.01; ***, P < 0.001, **** P <0.0001.

Article Snippet: For nude mice CD24 antibody treatment, mice were injected intraperitoneally 100 μg of CD24 antibody (ATG-031; cat#HY-P99176; MCE) twice a week.

Techniques: In Vivo, Injection, Control, Flow Cytometry, Membrane, Two Tailed Test, Quantitative RT-PCR, Expressing